Denosumab: all 207 studies that test it
Page 2 of 3. Open to participants first (15), then studies with results posted, then the rest; newest registration first within each.
- AMG 162 in the Treatment of Bone Loss in Subjects Undergoing Aromatase Inhibitor Therapy for Non-metastatic Breast CancerCompletedNCT00089661Phase 3Results posted
- Determine the Efficacy, Safety and Tolerability of Denosumab (AMG 162) in the Treatment of Postmenopausal Women With Low Bone Mineral DensityCompletedNCT00043186Phase 2Results posted
- A Study on Efficacy, Safety and Immunogenicity of 9MW0311 in Postmenopausal Women With OsteoporosisCompletedNCT06804590Phase 3
- NT-NOA - Novel Treatment of Some Men With Non-Obstructive AzoospermiaCompletedNCT06706414Phase 1/2
- A Study for the Evaluation of Efficacy and Safety of Prolia® in Participants With Glucocorticoid-induced Osteoporosis in Mainland ChinaActive, not recruitingNCT06588153Phase 4
- Study to Compare the Efficacy, Pharmacokinetics, Pharmacodynamics, Safety, and Immunogenicity of MAB-22 Versus Prolia®WithdrawnNCT06504966Phase 3
- Evaluation of Efficacy and Safety of Prolia in Subjects of Male Osteoporosis in Mainland ChinaActive, not recruitingNCT06332014Phase 4
- NAPO - Novel Approach for OligospermiaCompletedNCT06300229Phase 1/2
- Phase I Study to Compare the Pharmacokinetics, Pharmacodynamics, and Safety Between CT-P41 and US-licensed Prolia in Healthy Male SubjectsCompletedNCT06037395Phase 1
- Comparative Efficacy, Safety, PK, and Immunogenicity StudyActive, not recruitingNCT05853354Phase 3
- Osseointegrated Transdermal Femoral Amputation ProsthesesCompletedNCT05736640Not applicable
- Muscle Impact of Treating OsteoporosisActive, not recruitingNCT05666310Phase 4
- Denosumab vs Alendronate After VertebroplastyStatus unknownNCT05662358Not applicable
- Denosumab vs Zoledronate After Lumbar FusionStatus unknownNCT05638399Phase 3
- Denosumab vs Zoledronate After VertebroplastyCompletedNCT05598606Phase 4
- Effects of Denosumab on Bone Microarchitecture After Total Knee ArthroplastyStatus unknownNCT05559268Phase 4
- Effect of Anti-osteoporotic Medications on Nonalcoholic Fatty Liver DiseaseCompletedNCT05493761Phase 4
- Study of Denosumab for Prevention of Skeletal Disease Progression in Children With Fibrous DysplasiaCompletedNCT05419050Phase 2
- Denosumab Effect on Bone Quality and Function After Lumbar Fusion SurgeryCompletedNCT05415657Not applicable
- A Study to Evaluate the Efficacy and Safety of HLX14 vs. Denosumab Prolia® in Postmenopausal Women With Osteoporosis at High Risk of FractureCompletedNCT05352516Phase 3
- Efficacy and Safety of MW031 in PMO SubjectsCompletedNCT05215977Phase 3
- FITMI - First In Treating Male InfertilityActive, not recruitingNCT05212337Phase 2
- Effects of Denosumab on Bone Fusion in Osteoporotic Patients After Lumbar FusionStatus unknownNCT05203588Phase 4
- Denosumab vs Zoledronic Acid and Osteoporotic Compression FractureStatus unknownNCT05106517Phase 2/3
- PRevEnting FracturEs in REnal Disease - 1Active, not recruitingNCT05096195Phase 4
- Denosumab and Screw Fixation for Osteoporotic Compression FractureWithdrawnNCT05065164Phase 2/3
- Denosumab and Osteoporotic Vertebral Compression FractureCompletedNCT05058443Phase 2/3
- Anabolic Therapy in Postmenopausal OsteoporosisActive, not recruitingNCT05010590Phase 4
- Efficacy and Safety of MW032 and Xgeva® in Subjects With Bone Metastases From Solid TumorsCompletedNCT04812509Phase 3
- Romosozumab/Denosumab Study for Premenopausal IOPActive, not recruitingNCT04800367Phase 2
- Comparing of the Pharmacokinetic, Pharmacodynamic, Safety and Immunogenicity of MW032 and Xgeva® in Healthy AdultsCompletedNCT04798326Phase 1
- Comparing of the Pharmacokinetic, Pharmacodynamic, Safety and Immunogenicity of MW031 and Prolia® in Healthy AdultsCompletedNCT04798313Phase 1
- Studying the Effect of Denosumab on Preventing Breast Cancer in Women With a BRCA1 Germline MutationActive, not recruitingNCT04711109Phase 3
- Pharmacokinetics, Pharmacodynamics, Safety, Tolerability, and Immunogenicity Study of SB16 in Healthy Male SubjectsCompletedNCT04621318Phase 1
- Clinical Efficacy and Safety Comparative Study Between CMAB807 Injection and Prolia® .CompletedNCT04591275Phase 3
- Study of XGEVA® (Denosumab) in Chinese Adults and Skeletally Mature Adolescents With Giant Cell Tumor of the BoneActive, not recruitingNCT04586660Phase 4
- To Evaluate the Efficacy and Safety of QL1206 and Xgeva in Patients With Bone Metastases From Solid TumorsStatus unknownNCT04550949Phase 3
- Pharmacokinetic, Safety and Immunogenicity Phase I Study of HLX14 Versus Prolia® in Healthy Male SubjectsCompletedNCT04534582Phase 1
- A Phase I Study to Evaluate the Safety and Pharmacokinetics of CT-P41 and EU-approved Prolia in Healthy Male SubjectsCompletedNCT04512872Phase 1
- A Study to Evaluate Efficacy and Safety of Denosumab for Prevention and Treatment of Osteoporosis in 1st Time Liver Transplant Recipients.WithdrawnNCT04231682Phase 2
- Comparing of the Pharmacokinetic, Safety and Pharmacodynamic of QL1206 and Prolia® in Healthy AdultsStatus unknownNCT04213105Phase 1
- Alendronate Versus Denosumab in Kidney Transplant PatientsCompletedNCT04169698Phase 2/3
- Efficacy and Safety of QL1206 in the Treatment of Postmenopausal Osteoporosis With High Fracture RiskStatus unknownNCT04128163Phase 3
- Osteoporosis in Primary HyperparathyroidismStatus unknownNCT04085419Phase 4
- Treating Idiopathic Inflammatory Myopathies Related Reduced Bone Mineral Density With Denosumab or Zoledronic AcidStatus unknownNCT04034199Phase 3
- Phase 1 Study to Compare CMAB807 Injection to Prolia® in Healthy VolunteersCompletedNCT03925051Phase 1
- Denosumab in Combination With Enzalutamide in Progressive Metastatic Castrate-resistant Prostate Cancer and Bone Metastases.TerminatedNCT03869762Phase 2
- Denosumab Sequential TherapyCompletedNCT03868033Phase 4
- Denosumab for High Risk SMM and SLiM CRAB Positive, Early Myeloma PatientsCompletedNCT03792763Phase 2
- Study of the Efficacy of Lenvatinib Combined With Denosumab in the Treatment of Patients With Predominant Bone Metastatic Radioiodine Refractory Differentiated Thyroid CarcinomasStatus unknownNCT03732495Phase 2
- Biomarker Study of the Antitumoral Activity of Denosumab in the Pre- Operative Setting of Early Breast CancerStatus unknownNCT03691311Early Phase 1
- Comparing of the Pharmacokinetic, Safety and Pharmacodynamic of QL1206 and Xgeva® in Healthy AdultsCompletedNCT03651947Phase 1
- RANKL Inhibition and Breast Tissue BiomarkersCompletedNCT03629717Early Phase 1
- Reduced Dose-density of Denosumab for Unresectable GCTBTerminatedNCT03620149Phase 2
- Denosumab in Subjects With Giant Cell Rich Tumors of BoneStatus unknownNCT03605199Phase 2
- Denosumab Treatment for Fibrous DysplasiaActive, not recruitingNCT03571191Phase 2
- Study to Identify the Impact of Denosumab on the Immune System in Patients With HER2 Negative Breast CancerWithdrawnNCT03532087Phase 2
- Study Comparing Denosumab With Standard Treatment in Urothelial Cancer Patients With Bone MetastasesCompletedNCT03520231Phase 2
- Safety Assessment of Repeated Administration of TK006 in Patients With Breast Cancer-related Bone MetastasesStatus unknownNCT03487055Phase 1
- MiDeTe - microRNA Levels Under Denosumab and Teriparatide Therapy in Postmenopausal OsteoporosisCompletedNCT03472846Phase 4
- Denosumab: A Potential Treatment Option for Aneurysmal Bone CystsCompletedNCT03415477Phase 1/2
- Efficacy and Safety of Systemic Treatments of Bone Metastases From Kidney Cancer in Patients Treated With Targeted TherapiesTerminatedNCT03408652Phase 3
- Interest of Denosumab Treatment in Osteoporosis Associated to Systemic MastocytosisCompletedNCT03401060Phase 3
- Efficacy of Denosumab on Normal BMD in Women Receiving Adjuvant Aromatase Inhibitors for Early Breast CancerActive, not recruitingNCT03324932Phase 3
- Comparing Efficacy and Safety of AryoGen Pharmed Biosimilar Denosumab 60 mg (Arylia) Versus Prolia® in Improvement of Bone Mineral Densitometry (BMD) Among Osteoporotic Postmenopausal WomenStatus unknownNCT03293108Phase 3
- Denosumab and Pembrolizumab in Clear Cell Renal CarcinomaStatus unknownNCT03280667Phase 2
- Denosumab for the Treatment of Adult LCHCompletedNCT03270020Phase 2
- Characteristics and Mechanism of Denosumab-treated Giant Cell Tumor of BoneStatus unknownNCT03259152Phase 3
- Assessment of Anti-RANKL Antibody in Post-menopausal WomenStatus unknownNCT03242512Phase 1
- Assessment of TK006 in Patients With Breast Cancer-related Bone MetastasesStatus unknownNCT03239756Phase 1
- Effect of Denosumab in Erosion Healing in RACompletedNCT03239080Phase 2
- Denosumab Versus Zoledronic Acid in Thalassemia-Induced OsteoporosisTerminatedNCT03040765Phase 3
- Denosumab and Male Infertility: a RCTCompletedNCT03030196Phase 2
- The Efficacy of Denosumab in Incomplete Patients Spinal Cord InjuryTerminatedNCT03029442Phase 4
- Denosumab Versus Bisphosphonates (Alendronate) in GIOPCompletedNCT03005678Phase 4
- Presurgical Trial of Denosumab in Breast CancerCompletedNCT02900469Early Phase 1
- Denosumab in Metabolic Bone Disease in Chronic Intestinal Failure PatientsCompletedNCT02853539Phase 4
- A Study of Denosumab in Multiple Myeloma Patients With Renal InsufficiencyCompletedNCT02833610Phase 2
- Study Evaluating Denosumab on Bone and Vascular Metabolism in Osteoporotic Chronic Kidney DiseaseTerminatedNCT02792413Phase 4
- The Efficacy of Denosumab in Decreasing Periprosthetic Bone Loss in Patients With Total Knee ArthroplastyCompletedNCT02760979Phase 4
- 4-weekly Versus 12-weekly Administration of Bone-targeted Agents in Patients With Bone MetastasesCompletedNCT02721433Phase 4
- Denosumab as an add-on Neoadjuvant Treatment (GeparX)CompletedNCT02682693Phase 2
- Denosumab for Prevention of Bone Complications After Bone Marrow Transplantation in ChildrenWithdrawnNCT02677246Phase 1
- Denosumab for the Treatment of Osteoporosis in Children: A Pilot StudyCompletedNCT02632916Phase 2
- Impact of Denosumab in the Prevention of Bone Loss in Non-menopausal Women With Anorexia NervosaTerminatedNCT02567279Phase 3
- Denosumab vs Placebo in Patients With Thalassemia Major and OsteoporosisCompletedNCT02559648Phase 2
- Osteoclast Inhibition and Bone FormationCompletedNCT02554695Early Phase 1
- Longjohn Amgen Study - Effect of Denosumab...WithdrawnNCT02444585Phase 1
- TNFSF11 Inhibition and Fertility: a Prospective StudyCompletedNCT02422108Phase 2
- Denosumab for Glucocorticoid-treated Children With Rheumatic DisordersWithdrawnNCT02418273Phase 1/2
- The Efficacy of Denosumab in Active Crohn's DiseaseCompletedNCT02321280Phase 1/2
- Denosumab for Treating Periprosthetic Osteolysis.Status unknownNCT02299817Phase 2
- China HVT Safety, PK, PDCompletedNCT02135640Phase 1
- Study Investigating the Effect of Drugs Used to Treat Osteoporosis on the Progression of Calcific Aortic Stenosis.CompletedNCT02132026Phase 2
- Evaluate Time Associated With the Preparation & Administration of Denosumab/Pamidronate in Patients With Solid Tumors and Metastatic Bone DiseaseWithdrawnNCT02101164Phase 4
- Prevention of Symptomatic Skeletal Events With Denosumab Administered Every 4 Weeks Versus Every 12 WeeksTerminatedNCT02051218Phase 3
- Denosumab Administration After Spinal Cord InjuryStatus unknownNCT01983475Phase 4
- Effect of RANKL Inhibition on UV-induced ImmunosuppressionCompletedNCT01978483Phase 1
- A Study to Evaluate Denosumab in Young Patients With Primary Breast CancerTerminatedNCT01864798Phase 2
- Translational Therapy in Patients With Osteogenesis Imperfecta - A Pilot Trial on Treatment With the Rankl-Antibody DenosumabCompletedNCT01799798Phase 2